$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000110465913083298 Filed on November 12, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$320.0K	$39.00K	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.610M	$4.640M	$5.000M
YoY Change	3.36%	-7.2%	3.31%
% of Gross Profit
Research & Development	$9.120M	$10.11M	$11.50M
YoY Change	-17.47%	-12.08%	-16.13%
% of Gross Profit
Depreciation & Amortization	$400.0K	$430.0K	$420.0K
YoY Change	-6.98%	2.38%	10.53%
% of Gross Profit
Operating Expenses	$14.12M	$15.17M	$16.92M
YoY Change	-11.31%	-10.3%	-10.65%
Operating Profit		-$15.14M	-$16.92M
YoY Change		-10.53%	28.8%
Interest Expense	$40.00K	$7.000K	$19.00K
YoY Change	-98.5%	-63.16%	-40.63%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$0.00
YoY Change
Pretax Income	-$15.75M	-$14.59M	-$16.29M
YoY Change	18.78%	-10.44%	66.92%
Income Tax	-$3.510M	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$12.24M	-$14.59M	-$16.29M
YoY Change	22.19%	-10.44%	66.92%
Net Earnings / Revenue	-3824.06%	-37407.69%
Basic Earnings Per Share
Diluted Earnings Per Share	-$217.9K	-$294.0K	-$335.8K
COMMON SHARES
Basic Shares Outstanding	49.63M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$82.00M	$60.50M	$106.2M
YoY Change	-17.26%	-43.03%	52.81%
Cash & Equivalents	$43.64M	$30.05M	$24.27M
Short-Term Investments	$38.40M	$30.40M	$81.90M
Other Short-Term Assets	$5.195M	$1.700M	$3.077M
YoY Change	128.85%	-44.75%	2.57%
Inventory
Prepaid Expenses
Receivables	$1.100M	$2.100M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$88.28M	$64.30M	$112.5M
YoY Change	-15.62%	-42.83%	47.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.120M	$4.400M	$5.293M
YoY Change	-18.08%	-16.87%	194.06%
Goodwill	$11.61M
YoY Change
Intangibles	$23.00M
YoY Change
Long-Term Investments	$0.00
YoY Change
Other Assets	$552.0K	$400.0K	$442.0K
YoY Change	24.89%	-9.5%	-36.86%
Total Long-Term Assets	$39.29M	$4.800M	$5.735M
YoY Change	618.06%	-16.3%	129.4%
TOTAL ASSETS
Total Short-Term Assets	$88.28M	$64.30M	$112.5M
Total Long-Term Assets	$39.29M	$4.800M	$5.735M
Total Assets	$127.6M	$69.10M	$118.2M
YoY Change	15.87%	-41.55%	49.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.146M	$8.200M	$9.400M
YoY Change	1.47%	-12.77%	16.05%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$300.0K	$400.0K	$500.0K
YoY Change	-25.0%	-20.0%	-61.54%
Total Short-Term Liabilities	$10.46M	$8.598M	$9.930M
YoY Change	13.18%	-13.41%	-46.61%
LONG-TERM LIABILITIES
Long-Term Debt	$14.20M	$0.00	$400.0K
YoY Change	4633.33%	-100.0%	300.0%
Other Long-Term Liabilities	$714.0K	$34.00M	$31.10M
YoY Change	-97.72%	9.32%	33.48%
Total Long-Term Liabilities	$714.0K	$34.00M	$31.50M
YoY Change	-97.74%	7.94%	34.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.46M	$8.598M	$9.930M
Total Long-Term Liabilities	$714.0K	$34.00M	$31.50M
Total Liabilities	$11.18M	$42.60M	$41.50M
YoY Change	-72.68%	2.65%	-1.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$378.5M	-$366.3M	-$308.9M
YoY Change	18.7%	18.59%
Common Stock	$424.3M	$392.8M	$385.6M
YoY Change	9.32%	1.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$45.75M	$26.49M	$76.76M
YoY Change
Total Liabilities & Shareholders Equity	$127.6M	$69.11M	$118.2M
YoY Change	15.87%	-41.54%	49.82%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$12.24M	-$14.59M	-$16.29M
YoY Change	22.19%	-10.44%	66.92%
Depreciation, Depletion And Amortization	$400.0K	$430.0K	$420.0K
YoY Change	-6.98%	2.38%	10.53%
Cash From Operating Activities	-$8.120M	-$13.51M	-$7.200M
YoY Change	10.18%	87.64%	-44.57%
INVESTING ACTIVITIES
Capital Expenditures	-$50.00K	-$70.00K	-$230.0K
YoY Change	-66.67%	-69.57%	4.55%
Acquisitions
YoY Change
Other Investing Activities	-$7.910M	$20.25M	-$15.01M
YoY Change	-147.17%	-234.91%	-242.55%
Cash From Investing Activities	-$7.970M	$20.18M	-$15.23M
YoY Change	-147.98%	-232.5%	-247.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	29.68M	-100.0K	17.85M
YoY Change	6352.17%	-100.56%	-6050.0%
NET CHANGE
Cash From Operating Activities	-8.120M	-13.51M	-7.200M
Cash From Investing Activities	-7.970M	20.18M	-15.23M
Cash From Financing Activities	29.68M	-100.0K	17.85M
Net Change In Cash	13.59M	6.570M	-4.580M
YoY Change	40.1%	-243.45%	53.69%
FREE CASH FLOW
Cash From Operating Activities	-$8.120M	-$13.51M	-$7.200M
Capital Expenditures	-$50.00K	-$70.00K	-$230.0K
Free Cash Flow	-$8.070M	-$13.44M	-$6.970M
YoY Change	11.77%	92.83%	-45.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.96
	fold	Deemed Dividend DeemedDividend	19424000	USD
	fold	Preferred Stock Accretion PreferredStockAccretion	802000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	20000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	20000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1284000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1318000	USD
CY2013Q3	fold	Warrants And Rights Outstanding Current WarrantsAndRightsOutstandingCurrent	34000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8598000	USD
CY2012Q4	fold	Warrants And Rights Outstanding Noncurrent WarrantsAndRightsOutstandingNoncurrent	908000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	14536000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	19000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	7000	USD
	us-gaap	Interest Expense InterestExpense	77000	USD
CY2013Q3	fold	Research Revenue ResearchRevenue	39000	USD
	us-gaap	Interest Expense InterestExpense	26000	USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	fold	Research Revenue ResearchRevenue	39000	USD
	us-gaap	Interest Expense InterestExpense	2448000	USD
CY2012Q3	fold	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-553000	USD
CY2013Q3	fold	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-517000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	556000	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	556000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	387539000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14000	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-318889000	USD
	fold	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	1941000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	26489000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	110088000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	69106000	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	21000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16290000	USD
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49631672	shares
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-14589000	USD
	fold	Research Revenue ResearchRevenue	11591000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-38770000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13086000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-374993000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-16290000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	418000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-14589000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-38770000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	15174000	USD
	us-gaap	Operating Expenses OperatingExpenses	55419000	USD
	fold	Collaboration Revenue CollaborationRevenue	64382000	USD
	us-gaap	Operating Expenses OperatingExpenses	48430000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	18411000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	121914000	USD
	us-gaap	Operating Expenses OperatingExpenses	511674000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-47396000	USD
CY2013Q3	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	34019000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16916000	USD
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	392213000	USD
CY2012Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11499000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-366285000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8501000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15135000	USD
CY2012Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	92000	USD
CY2013Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	10110000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	39226000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	32824000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	348717000	USD
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	36000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	235000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	147000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-389760000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4995000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4635000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14909000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14288000	USD
	us-gaap	Restructuring Charges RestructuringCharges	1522000	USD
	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	1030000	USD
CY2012Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	422000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-366285000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16290000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14589000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-47396000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-386511000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.88
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48513647	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49621188	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49621188	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44255885	shares
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	522000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4743000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4674000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	46603000	USD
	fold	Share Based Compensation Non Employees ShareBasedCompensationNonEmployees	853000	USD
	fold	Stock Based License Payments StockBasedLicensePayments	1220000	USD
	fold	Change In Fair Value Of Warrant Liability Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities ChangeInFairValueOfWarrantLiabilityAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities	1941000	USD
	fold	Change In Fair Value Of Warrant Liability Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities ChangeInFairValueOfWarrantLiabilityAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities	-2427000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16270000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	33000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	33000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38737000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	2000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14587000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47405000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-366280000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	5000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-9000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	525000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-28000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-388000	USD
	fold	Beneficial Conversion Feature Related To Bridge Financing BeneficialConversionFeatureRelatedToBridgeFinancing	135000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-1859000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-1104000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	2121000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2826000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-578000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1692000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-267000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	466000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-280000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-679000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8166000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-268000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	3601000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	34019000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-26370000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-37674000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-266026000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	47445000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	68348000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	823790000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	99320000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	33654000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	854349000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4167000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	645000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18858000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-56042000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	34049000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-49417000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	143022000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	193441000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5000000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	5587000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	1139000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	299000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	4355000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	966000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3341000	USD
	fold	Proceeds From Exercise Of Warrants Common And Preferred ProceedsFromExerciseOfWarrantsCommonAndPreferred	264000	USD
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	5611000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	995000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	4753000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	81017000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-299000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	345490000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-1395000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-3924000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	30047000	USD
	us-gaap	Interest Paid InterestPaid	72000	USD
	us-gaap	Interest Paid InterestPaid	24000	USD
	us-gaap	Interest Paid InterestPaid	2141000	USD
	fold	Conversion Of Warrants To Common Stock ConversionOfWarrantsToCommonStock	386000	USD
	fold	Conversion Of Notes Payable To Preferred Stock ConversionOfNotesPayableToPreferredStock	5000000	USD
	fold	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	148951000	USD
	fold	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	802000	USD
	fold	Beneficial Conversion Feature Related To Issuance Of Series C Redeemable Convertible Preferred Stock BeneficialConversionFeatureRelatedToIssuanceOfSeriesCRedeemableConvertiblePreferredStock	19424000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25668000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24273000	USD
	dei	Entity Registrant Name EntityRegistrantName	AMICUS THERAPEUTICS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49631672	shares
CY2010Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4950000	shares
CY2012Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	11500000	shares
CY2010Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1900000	shares
CY2010Q1	fold	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	17100000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	62000000	USD
CY2010Q1	fold	Stock Issued During Period Shares Collaboration Agreement StockIssuedDuringPeriodSharesCollaborationAgreement	4900000	shares
CY2010Q1	fold	Number Of Shares Of Common Stock Sold In One Unit NumberOfSharesOfCommonStockSoldInOneUnit	1	shares
CY2010Q1	fold	Number Of Warrants Sold In One Unit NumberOfWarrantsSoldInOneUnit	1	shares
CY2010Q1	fold	Portion Of Share Purchased In One Unit PortionOfSharePurchasedInOneUnit	0.375	shares
CY2010Q1	fold	Warrant Term WarrantTerm	P4Y
CY2010Q1	fold	Exercise Period Of Warrant On Or After Issued ExercisePeriodOfWarrantOnOrAfterIssued	P9M
CY2010Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	4.43
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1400000	shares
CY2012Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	33971000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	30047000	USD
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	11000	USD
CY2012Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	99108000	USD
CY2012Q4	fold	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	99122000	USD
CY2013Q3	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	9000	USD
CY2013Q3	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	4000	USD
CY2013Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	60490000	USD
CY2013Q3	fold	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	60495000	USD
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	65151000	USD
CY2013Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	30443000	USD
CY2013Q3	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	30448000	USD
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	10000	USD
CY2012	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	33100000	USD
CY2013Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	14800000	USD
CY2012Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	37000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4000	USD
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	17000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2012Q1	us-gaap	Share Price SharePrice	5.70
CY2012Q1	fold	Proceeds From Issuance Of Common Stock Gross ProceedsFromIssuanceOfCommonStockGross	65600000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	20000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	33000	USD
CY2010Q1	fold	Proceeds From Issuance Of Common Stock Gross ProceedsFromIssuanceOfCommonStockGross	18500000	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1598000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4743000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4674000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1517000	USD
CY2013Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2013Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
	fold	Fair Value Inputs Number Of Inputs Used In Fair Value Classification FairValueInputsNumberOfInputsUsedInFairValueClassification	6	item
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.760	pure
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.597	pure
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0019	pure
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0003	pure
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y5M1D
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5M1D
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.00	pure
	fold	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-874000	USD
CY2013Q3	fold	Common Stock Voting Rights For Each Share Held CommonStockVotingRightsForEachShareHeld	1	item
CY2010Q1	us-gaap	Share Price SharePrice	3.74
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9000	USD
	fold	Change In Fair Value Of Warrant Liability Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities ChangeInFairValueOfWarrantLiabilityAdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivities	-874000	USD
	fold	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-2427000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	252000	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	39000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	39000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8708000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3300000	USD
CY2012	fold	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	500000	shares

Files In Submission

Name	View Source	Status
0001104659-13-083298-index-headers.html	Edgar Link	pending
0001104659-13-083298-index.html	Edgar Link	pending
0001104659-13-083298.txt	Edgar Link	pending
0001104659-13-083298-xbrl.zip	Edgar Link	pending
a13-19744_110q.htm	Edgar Link	pending
a13-19744_1ex31d1.htm	Edgar Link	pending
a13-19744_1ex31d2.htm	Edgar Link	pending
a13-19744_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fold-20130930.xml	Edgar Link	completed
fold-20130930.xsd	Edgar Link	pending
fold-20130930_cal.xml	Edgar Link	unprocessable
fold-20130930_def.xml	Edgar Link	unprocessable
fold-20130930_lab.xml	Edgar Link	unprocessable
fold-20130930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2013 Q4 Form 10-Q Financial Statement

#000110465913083298 Filed on November 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2013 Q4 Form 10-Q Financial Statement

#000110465913083298 Filed on November 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold